Short answer
Tarsus Pharmaceuticals, Inc. (TARS) filed an 8-K current report with the SEC on June 29, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). Quorum established with 38,237,214 shares represented from 43,023,959 outstanding.
Tarsus Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Quorum established with 38,237,214 shares represented from 43,023,959 outstanding
- All four Class III director nominees elected through 2029, including Andrew Goldberg with 26,733,789 votes
- Executive compensation approved on an advisory basis, with 34,486,767 votes for and 238,014 against
- Ernst & Young LLP ratified as independent auditor for fiscal 2026, with 38,219,521 votes for
- Board retains eight directors, including the four elected nominees and four continuing members
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tarsus Pharmaceuticals, Inc. 8-K filings
Get the next TARS 8-K as it lands
Follow TARS for push alerts, or ask the research agent what this filing means.